Navigation Links
183 New Medicines in Development for Diabetes
Date:12/11/2009

WASHINGTON, Dec. 11 /PRNewswire-USNewswire/ -- Nabe News in Brooklyn, New York recently reported that 183 new medicines are in development to fight diabetes. The report details a record number of drugs for this chronic disease currently in human clinical trials and awaiting approval by the U.S. Food and Drug Administration. The report was released by America's pharmaceutical research and biotechnology companies (PhRMA).

Diabetics do not produce or properly use insulin, a hormone needed to convert sugar, starches and other food into energy. This chronic disease affects 24.7 percent of Brooklyn's adults, or 449,900 people, according to the Centers for Disease Control and Prevention.

"This killer thrives in communities like ours, where poverty and fast food are prevalent," said Dr. Richard Becker, president and CEO of the Brooklyn Hospital Center.

Rep. Edolphus Towns, who suffers from diabetes, attended the event at the Brooklyn Hospital Center as well.

"Developing new drugs to treat diabetes here in New York City will help address one of the major diseases affecting our community," the lawmaker said. Of New York's five boroughs, Brooklyn has the second highest rate of diabetes.

According to PhRMA, one of the drugs in development significantly improves long-term blood sugar control and targets the dysfunction of pancreas cells, a dysfunction that causes high sugar level in type 2 diabetes, the most common form of the disease. Another medicine in development stimulates the release of insulin only when glucose levels become too high and by suppressing appetite in patients with type 2 diabetes.

"The medicines now in the research pipelines are contributing significantly to the incredible progress made by America's pharmaceutical research and biotechnology companies in developing new treatments for diabetes and related conditions," said Ed Belkin, PhRMA vice president for communications and public affairs.

To read the full story, go to the Nabe News web site.

SOURCE Pharmaceutical Research and Manufacturers of America


'/>"/>
SOURCE Pharmaceutical Research and Manufacturers of America
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. 92 Medicines and Vaccines now in Development for HIV/AIDS
2. New Report Offers Hope for Closing Health Gap for African Americans, With Nearly 700 Medicines in Pipeline
3. Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency
4. ActivBiotics Receives Orphan Drug Designation from the European Medicines Agency for Superoxide Dismutase Mimetic, M40403, in Oral Mucositis Indication
5. Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Acute Myelogenous Leukemia
6. Report on 750 New Medicines in Development for Cancer Released in Baton Rouge
7. European Medicines Agency Adopts Positive Opinion for Ranolazine for Treatment of Chronic Angina
8. AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines
9. More Than 300 New Medicines Being Developed for Mental Illnesses
10. Report on 300 New Medicines in Development for Heart Disease and Stroke Released in Indianapolis
11. New Report Shows Record Number of Medicines in Development to Treat Leading Causes of Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... SYDNEY , June 26, 2016 One of ... , has announced the formation of a new biotechnology company, Noxopharm ... raise $6m in an IPO and to list on the ASX. ... drug candidate, NOX66, ready to enter a Phase 1 clinical study ... been designed to address one of the biggest problems facing cancer ...
(Date:6/26/2016)... June 27, 2016 Jazz Pharmaceuticals plc (Nasdaq: ... under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as ... Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: CPXX ) ... Daylight Time). As previously announced on May ... definitive merger agreement under which Jazz Pharmaceuticals has commenced ...
(Date:6/26/2016)... Ontario , June 27, 2016  VMS Rehab ... Company,s Board will take whatever measures required to build ... Company,s stock which is currently listed on the OTC ... Wexler, Company Chairman and CEO, "We are seeing an ... difficult to understand, not only by the Company, but ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... ... authorized OSHA Training Institute Education Center headquartered in Northern California, has issued an ... extreme heat at their worksites. Employers with workers exposed to high temperatures ...
(Date:6/27/2016)... ... 27, 2016 , ... "FCPX editors can now reveal their media with growing ... said Christina Austin - CEO of Pixel Film Studios. , ProSlice Color brings ... users can now reveal the media of their split screens with growing colorful panels. ...
(Date:6/27/2016)... ... June 27, 2016 , ... TherapySites, ... its affiliation with Tennessee Counseling Association. This new relationship allows TherapySites ... Tennessee Counseling Association, adding exclusive benefits and promotional offers. , "TCA is extremely ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... announced its strategic partnership with Connance, a healthcare industry leader providing predictive ... proven, proprietary technology combine to provide health systems, hospitals and ambulatory surgical ...
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... ... cutting edge technology to revolutionize the emergency ambulance transport experience for the millions ... aware of how Uber has disrupted the taxi industry through the use of ...
Breaking Medicine News(10 mins):